IP Library › Granted Patent US 12,551,327
Granted Patent B2
US 12,551,327 · App. 17/965,693 · Granted Feb 17, 2026

Biodegradable stent

Inventors: Karim Tarabein (Shaker Heights, OH); James J. Scutti (Arlington, MA)
Assignee: BOSTON SCIENTIFIC SCIMED, INC.
A61F2/04A61F2002/041A61F2002/044A61F2002/045A61F2/06A61F2210/0004A61F2250/0004A61F2250/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,327
App. No.
17/965,693
Granted
Feb 17, 2026
Kind
B2
Abstract

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.

Claims (38)

1 . A stent, comprising;

a tubular scaffold having a first end and a second end, the tubular scaffold including:

a plurality of filaments extending between the first end and the second end, the plurality of filaments defining a first tubular biodegradable region and a second tubular biodegradable region;

the first tubular biodegradable region positioned at a discrete location longitudinally adjacent to the second tubular biodegradable region such that the first tubular biodegradable region is located closer to the first end than the second tubular biodegradable region, wherein each of the first tubular biodegradable region and the second tubular biodegradable region defines a tubular region extending circumferentially entirely around a lumen of the tubular scaffold;

wherein the plurality of filaments defining the first tubular biodegradable region includes a plurality of first biodegradable portions arranged around the tubular region of the first tubular biodegradable region, and wherein the plurality of filaments defining the second tubular biodegradable region includes a plurality of second biodegradable portions arranged around the tubular region of the second tubular biodegradable region;

wherein the first biodegradable portions of the plurality of filaments located within the first tubular biodegradable region are configured to degrade at a first rate of degradation;

wherein the second biodegradable portions of the plurality of filaments located within the second tubular biodegradable region are configured to degrade at a second rate of degradation; and

wherein the first rate of degradation is faster than the second rate of degradation such that the first tubular biodegradable region having the first biodegradable portions fully degrades faster than the second tubular biodegradable region having the second biodegradable portions.

2 . The stent of claim 1 , further comprising a first catalyst disposed along discrete portions of each of the plurality of filaments in the first tubular biodegradable region.

3 . The stent of claim 2 , wherein the first catalyst includes an enzyme.

4 . The stent of claim 3 , wherein the plurality of filaments in the second tubular biodegradable region are devoid of the first catalyst.

5 . The stent of claim 2 , wherein the first catalyst includes a ferric particle.

6 . The stent of claim 2 , wherein the plurality of filaments in the second tubular biodegradable region are devoid of the first catalyst.

7 . The stent of claim 2 , wherein the first catalyst is configured to degrade the first tubular biodegradable region at the first rate of degradation.

8 . The stent of claim 2 , wherein the first catalyst is configured to be activated by an activation source, wherein the activation source triggers the first catalyst to accelerate the rate of degradation of the first tubular biodegradable region.

9 . The stent of claim 8 , wherein the activation source includes an activation fluid.

10 . The stent of claim 8 , wherein the activation source includes inductive heating.

11 . The stent of claim 1 , wherein the first tubular biodegradable region includes a first biodegradable material and a second biodegradable material, and wherein the second biodegradable material is encased in the first biodegradable material.

12 . The stent of claim 11 , wherein a rate of degradation of the second biodegradable material is slower than a rate of degradation of the first biodegradable material.

13 . The stent of claim 1 , wherein the first tubular biodegradable region, the second tubular biodegradable region, or both the first and the second tubular biodegradable regions include a multiphasic material.

14 . A stent, comprising:

a tubular scaffold having a proximal end and a distal end, the tubular scaffold including:

a first filament extending between the proximal end and the distal end;

a second filament extending between the proximal end and the distal end, wherein the first filament crosses the second filament at a first activation site; and

an activation material including a first catalyst disposed along the first activation site, wherein the first catalyst is configured to dissolve portions of the first and second filaments in contact with the first catalyst at a faster rate than portions of the first and second filaments which are devoid of the catalyst.

15 . The stent of claim 14 , wherein the catalyst includes an enzyme.

16 . The stent of claim 14 , further comprising a second activation site located along the first filament, and wherein a second catalyst is disposed along the second activation site, and wherein the degradation rate of the second catalyst is different from the degradation rate of the first catalyst.

17 . The stent of claim 14 , wherein the first filament and/or the second filament includes a multiphasic material.

18 . A stent, comprising;

a tubular scaffold having a proximal end and a distal end, the tubular scaffold including:

a plurality of filaments extending between the proximal end and the distal end, each filament including:

a first biodegradable material having a first rate of degradation;

a second biodegradable material having a second rate of degradation;

wherein the first rate of degradation is faster than the second rate of degradation;

wherein the second biodegradable material is surrounded by the first biodegradable material; and

wherein the second biodegradable material is located in a plurality of discontinuous regions within the first biodegradable material.

19 . The stent of claim 18 , further comprising a first catalyst disposed along discrete portions of each of the plurality of filaments.

20 . The stent of claim 19 , further comprising a second catalyst disposed along discrete portions of each of the plurality of filaments, and wherein a degradation rate of the second catalyst is different from a degradation rate of the first catalyst.

Continuity (3)
Continuation 16672138 · Nov 1, 2019
Provisional Application 62754993 · Nov 2, 2018
Related Publication 20230044894A1 · Feb 9, 2023
References Cited (39)
US 5957975A · Afont et al. · 1999 [cited by applicant]
US 7641983B2 · Stinson · 2010 [cited by applicant]
US 7651527B2 · Krivoruchko et al. · 2010 [cited by applicant]
US 7833261B2 · Chen et al. · 2010 [cited by applicant]
US 7955381B1 · Wang et al. · 2011 [cited by applicant]
US 8057534B2 · Boismier et al. · 2011 [cited by applicant]
US 8062351B2 · Burnside et al. · 2011 [cited by applicant]
US 8267990B2 · Gale et al. · 2012 [cited by applicant]
US 8388676B2 · Stinson · 2013 [cited by applicant]
US 8394488B2 · Dave et al. · 2013 [cited by applicant]
US 8709070B2 · Wang et al. · 2014 [cited by applicant]
US 8764813B2 · Jantzen · 2014 [cited by examiner]
US 8870945B2 · Dave et al. · 2014 [cited by applicant]
US 8961585B2 · Ma et al. · 2015 [cited by applicant]
US 9248034B2 · Hossainy et al. · 2016 [cited by applicant]
US 9283097B2 · Wang et al. · 2016 [cited by applicant]
US 9326870B2 · Berglund et al. · 2016 [cited by applicant]
US 9333099B2 · Pacetti et al. · 2016 [cited by applicant]
US 9474637B2 · Zhao · 2016 [cited by applicant]
US 9561308B2 · Schaffer · 2017 [cited by applicant]
US 10028851B2 · Dugan et al. · 2018 [cited by applicant]
US 10105246B2 · Liu · 2018 [cited by applicant]
US 20050043783A1 · Amis et al. · 2005 [cited by applicant]
US 20070254012A1 · Ludwig et al. · 2007 [cited by applicant]
US 20080199510A1 · Ruane et al. · 2008 [cited by applicant]
US 20100004733A1 · Atanasoska et al. · 2010 [cited by applicant]
US 20100087916A1 · Bayer et al. · 2010 [cited by applicant]
US 20100292776A1 · Weber et al. · 2010 [cited by applicant]
US 20110022158A1 · Atanasoska et al. · 2011 [cited by applicant]
US 20110046721A1 · Arps · 2011 [cited by applicant]
US 20110319977A1 · Pandelidis et al. · 2011 [cited by applicant]
US 20130138219A1 · Toomey et al. · 2013 [cited by applicant]
US 20130144376A1 · Dave et al. · 2013 [cited by applicant]
US 20130184809A1 · Stinson · 2013 [cited by applicant]
US 20150057745A1 · Gale et al. · 2015 [cited by applicant]
US 20150342764A1 · Ramzipoor et al. · 2015 [cited by applicant]
US 20170119936A1 · Schaffer et al. · 2017 [cited by applicant]
US 20190209354A1 · Scanlon et al. · 2019 [cited by applicant]
International Search Report and Written Opinion dated Apr. 21, 2020 for International Application No. PCT/US2019/059521. [cited by applicant]